All tenofovir alafenamide articles
-
NewsEight-year results from two randomized phase 3 trials of tenofovir alafenamide for chronic hepatitis B virus infection in China
Tenofovir alafenamide (TAF) has demonstrated comparable efficacy to tenofovir disoproxil fumarate (TDF), with improved renal and bone safety, in Chinese participants with chronic hepatitis B enrolled in two Phase 3 trials.